RxIndia
Loading clinical data...
Loading clinical data...
Authoritative Clinical Reference
| Parameter | Recommendation |
|
Starting dose
|
20–40 mg twice daily |
|
Titration
|
Increase every 1–2 weeks based on blood pressure response |
|
Usual maintenance dose
|
80–160 mg/day in 2–3 divided doses |
|
Maximum dose
|
320 mg/day |
| Parameter | Recommendation |
|
Starting dose
|
20 mg twice daily |
|
Titration
|
Increase gradually based on clinical response and heart rate |
|
Usual maintenance dose
|
40–80 mg twice or thrice daily |
|
Maximum dose
|
320 mg/day |
| Parameter | Recommendation |
|
Starting dose
|
20–40 mg three times daily |
|
Titration
|
Adjust as needed for rate control |
|
Usual maintenance dose
|
120–240 mg/day in divided doses |
|
Maximum dose
|
320 mg/day |
| Parameter | Recommendation |
|
Starting dose
|
20 mg twice daily |
|
Titration
|
Increase based on tremor control and tolerability |
|
Usual maintenance dose
|
40–80 mg twice daily |
|
Maximum dose
|
160 mg/day |
|
Duration
|
Long-term; reassess periodically |
| Parameter | Recommendation |
|
Starting dose
|
20 mg twice daily |
|
Titration
|
Increase to 40 mg twice daily after 2 weeks if tolerated |
|
Usual maintenance dose
|
40–80 mg twice daily |
|
Maximum dose
|
160 mg/day |
|
Duration
|
Minimum 2–3 months trial; reassess efficacy |
| Parameter | Recommendation |
|
Starting dose
|
20–40 mg as needed, 30–60 minutes before anticipated anxiety-provoking situation |
|
Titration
|
Not applicable for PRN use |
|
Usual maintenance dose
|
20–40 mg PRN |
|
Maximum dose
|
80 mg/day |
| Parameter | Recommendation |
|
Starting dose
|
0.5–1 mg/kg/day in 2–3 divided doses |
|
Titration
|
Increase gradually based on heart rate response and tolerability |
|
Usual maintenance dose
|
1–2 mg/kg/day in divided doses |
|
Maximum dose
|
4 mg/kg/day |
|
Minimum age
|
Not recommended below 12 years except under paediatric cardiologist guidance |
| Renal Function | Recommendation |
| Mild to moderate impairment | No dose adjustment required |
| Severe impairment (CrCl <30 mL/min) | Use with caution; monitor heart rate and blood pressure closely |
| Haemodialysis | Limited data; minimal dialysis clearance expected; no supplemental dose required |
| Severity | Recommendation |
| Mild impairment | No specific adjustment required; monitor heart rate and blood pressure |
| Moderate impairment | Consider dose reduction (start at lower end of dose range); slower titration |
| Severe impairment | Avoid or use only with specialist input; significant risk of accumulation due to hepatic metabolism |
| Consideration | Recommendation |
| Overall safety | Use only if clearly needed; limited human pregnancy data |
| Risk | Potential for fetal bradycardia, hypoglycaemia, intrauterine growth restriction |
| Preferred alternatives | Labetalol (hypertension in pregnancy); metoprolol (arrhythmias) — better established safety data |
| When it may be used | Only if preferred alternatives not suitable; under obstetric and specialist supervision |
| Monitoring | Fetal growth (serial ultrasound), fetal heart rate; neonatal heart rate, blood pressure, and glucose for 48–72 hours post-delivery |
| Consideration | Recommendation |
| Compatibility | Compatible with breastfeeding with caution |
| Drug levels in milk | Low levels expected |
| Preferred alternatives | Propranolol, labetalol, metoprolol (more breastfeeding data available) |
| Infant monitoring | Heart rate, feeding difficulties, lethargy, poor weight gain, signs of beta-blockade |
| Consideration | Recommendation |
| Starting dose | 10–20 mg twice daily |
| Titration | Slower titration required — increase dose at 2–4 week intervals |
| Risks | Bradycardia, orthostatic hypotension, dizziness, falls, fatigue, confusion, cognitive effects |
| Monitoring | Blood pressure (supine and standing), heart rate, renal function, mental status |
| Interacting Drug | Effect / Mechanism | Recommendation |
| Verapamil, Diltiazem | Additive negative chronotropic and dromotropic effects; risk of severe bradycardia, AV block, heart failure |
Avoid concurrent use; avoid IV verapamil/diltiazem in patients on oxprenolol
|
| Clonidine | Risk of severe rebound hypertension if clonidine stopped abruptly |
Discontinue oxprenolol several days before stopping clonidine; taper clonidine slowly
|
| Digoxin | Additive bradycardia and AV block risk |
Monitor heart rate closely; consider digoxin dose reduction
|
| Class I antiarrhythmics (quinidine, disopyramide, flecainide) | Enhanced myocardial depression; additive negative inotropic effects |
Avoid combination or use with extreme caution
|
| MAOIs (non-selective) | May potentiate hypotensive effects |
Avoid combination
|
| Fingolimod | Additive bradycardia risk |
Avoid initiation of fingolimod in patients on oxprenolol
|
| Interacting Drug | Effect / Mechanism | Recommendation |
| Insulin, Sulfonylureas | Beta-blockade masks hypoglycaemia symptoms (tachycardia, tremor) | Monitor blood glucose closely; educate patient |
| NSAIDs | May attenuate antihypertensive effect via prostaglandin inhibition | Monitor blood pressure |
| Rifampicin | May reduce oxprenolol levels via CYP enzyme induction | Monitor clinical response; may need dose adjustment |
| Amiodarone | Additive bradycardia risk | Monitor heart rate and ECG |
| Tricyclic antidepressants | May increase hypotensive effect; altered beta-blocker metabolism | Monitor blood pressure |
| SSRIs (fluoxetine, paroxetine) | CYP2D6 inhibition may increase oxprenolol levels | Monitor for excessive beta-blockade |
| Anaesthetic agents | Enhanced hypotensive effect | Inform anaesthetist; do not discontinue abruptly before surgery |
| Alcohol | Additive hypotensive effects | Advise moderation |
| Ergot alkaloids | Additive vasoconstriction | Monitor for peripheral ischaemia |
| Adverse Effect | Clinical Note |
| Bronchospasm | Especially in patients with asthma or reactive airway disease; discontinue immediately |
| Severe bradycardia or AV block | May require atropine, temporary pacing, or discontinuation |
| Severe hypotension | Risk heightened in elderly or overdose; supportive care required |
| Worsening heart failure | Monitor closely; may require dose reduction or discontinuation |
| Rebound phenomena on abrupt withdrawal | Tachycardia, angina, myocardial infarction — always taper gradually |
| Depression, confusion, hallucinations | More common in elderly; consider dose reduction or alternative agent |
| Peripheral ischaemia | Worsening of Raynaud’s phenomenon or claudication |
| Phase | Parameters |
|
Baseline
|
Blood pressure (supine and standing), resting heart rate, ECG (if arrhythmia indication), renal function, hepatic function, blood glucose (in diabetics) |
|
After initiation/dose change
|
Heart rate and blood pressure at 1–2 weeks |
|
Long-term
|
Blood pressure, heart rate every 2–3 months; periodic ECG in arrhythmia patients; periodic assessment of mood and exercise tolerance |
| Strength | Approximate Price Range (per tablet) |
| 20 mg | ₹2–₹4 (generic) |
| 40 mg | ₹5–₹8 (branded) |
| 80 mg | ₹8–₹12 (branded) |
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Help us improve our clinical database for the medical community.